Sound waves to soothe schizophrenia?
NCT ID NCT07621549
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether low-intensity ultrasound, aimed at the brain, is safe and could help with schizophrenia symptoms. Eighty adults with schizophrenia will receive the non-invasive treatment. Researchers will check safety and look for any improvements in mood, thinking, and psychiatric symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcranial ultrasound stimulation (TUS)
- What this could lead to
- If it works, this could point toward a new, non-invasive way to ease schizophrenia symptoms and improve daily life.
- What could go wrong
- This is an early feasibility study with only 80 people. It focuses on safety first, so symptom improvement is not guaranteed. The effects may be small or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age: 18-65 years old. 2. Gender: Both males and females are eligible. 3. Diagnosed with schizophrenia according to DSM-V criteria (a PANSS total score of less than approximately 90). 4. No changes in medication (same dosage and same drug) for at least one month. Exclusion Criteria: 1. History of head injury with loss of consciousness for more than 10 minutes or a history of brain surgery. 2. Any history of epilepsy. 3. Presence of a family history of epilepsy 4. Heavy alcohol consumption or use of illicit drugs (substance dependence within the last 6 months or substance abuse within the last month). 5. Any significant medical conditions that could affect normal brain function (including but not limited to stroke, CNS infections or tumors, or other major neurological diseases). 6. Presence of a cardiac pacemaker, implanted medication pump, intracardiac lines, or acute/unstable cardiac disease, as well as intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metallic objects in or near the head (excluding oral metal objects) 7. Pregnant or breastfeeding women. 8. Presence of suicidal or self-harming tendencies 9. Current use of medications known to lower the seizure threshold or increase the risk of suicidal behavior 10. Presence of severe and uncontrolled systemic diseases (e.g., heart failure, liver failure, renal failure, vitamin B12 deficiency, hypothyroidism), as determined by the investigator to be unsuitable for study participation 11. Patients with uncontrolled diabetic retinopathy accompanied by active fundus hemorrhage 12. Concurrent participation in other clinical studies or clinical trials 13. Presence of contraindications to the medical devices used in this study (including pulsed ultrasound, EEG, and CT), such as unheindividuals with obvious head trauma, unhealed head surgery, or significant physical or psychiatric symptoms. 14. Any other conditions deemed unsuitable for participation in the clinical trial as assessed by the physician.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizo affective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Far Eastern Memorial Hospital
RECRUITINGNew Taipei City, 220, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia